Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer’s Disease Lymphoblast Alterations

[1]  M. L. de Ceballos,et al.  Indazolylketones as new multitarget cannabinoid drugs. , 2019, European journal of medicinal chemistry.

[2]  Ping Li,et al.  Observation of Acetylcholinesterase in Stress-Induced Depression Phenotypes by Two-Photon Fluorescence Imaging in the Mouse Brain. , 2019, Journal of the American Chemical Society.

[3]  C. Pérez,et al.  Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer’s Disease , 2018, CNS Drugs.

[4]  Hongyun Wang,et al.  Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia. , 2017, Central nervous system agents in medicinal chemistry.

[5]  Maria Vanina Martinez,et al.  Hybridizing Feature Selection and Feature Learning Approaches in QSAR Modeling for Drug Discovery , 2017, Scientific Reports.

[6]  T. Ulas,et al.  A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice , 2017, Nature Medicine.

[7]  G. Du,et al.  DL0410 Ameliorates Memory and Cognitive Impairments Induced by Scopolamine via Increasing Cholinergic Neurotransmission in Mice , 2017, Molecules.

[8]  Jihong Wu,et al.  Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons , 2016, Redox biology.

[9]  M. Staufenbiel,et al.  A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice , 2015, Molecular Neurodegeneration.

[10]  J. Molina,et al.  G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson’s Disease Patients , 2015, Molecular Neurobiology.

[11]  S. Pasquaré,et al.  Normal aging in rats and pathological aging in human Alzheimer’s disease decrease FAAH activity: Modulation by cannabinoid agonists , 2014, Experimental Gerontology.

[12]  Mohammad A Kamal,et al.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus. , 2014, CNS & neurological disorders drug targets.

[13]  A. Alzualde,et al.  PGRN haploinsufficiency increased Wnt5a signaling in peripheral cells from frontotemporal lobar degeneration-progranulin mutation carriers , 2014, Neurobiology of Aging.

[14]  I. Ferrer,et al.  Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic , 2014, Front. Pharmacol..

[15]  M. García-Arencibia,et al.  Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. , 2014, European journal of medicinal chemistry.

[16]  F. Bermejo-Pareja,et al.  Downregulation of extracellular signal-regulated kinase 1/2 activity by calmodulin KII modulates p21Cip1 levels and survival of immortalized lymphocytes from Alzheimer’s disease patients , 2013, Neurobiology of Aging.

[17]  C. Pérez,et al.  Multitarget cannabinoids as novel strategy for Alzheimer disease. , 2013, Current Alzheimer research.

[18]  O. Dı́az-Ruiz,et al.  Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson’s disease , 2012, BMC Neuroscience.

[19]  C. Cotman,et al.  An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease , 2012, Neurobiology of Aging.

[20]  T. Arendt.  Cell Cycle Activation and Aneuploid Neurons in Alzheimer's Disease , 2012, Molecular Neurobiology.

[21]  P. Chameau,et al.  Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors , 2012, Proceedings of the National Academy of Sciences.

[22]  Naaheed Mukadam,et al.  Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia , 2012, International Psychogeriatrics.

[23]  M. Delgado,et al.  Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice , 2012, Journal of Neuroinflammation.

[24]  A. M. Martín-Moreno,et al.  Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease , 2011, Molecular Pharmacology.

[25]  Masahiko Watanabe,et al.  Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. , 2011, Brain : a journal of neurology.

[26]  I. Grundke‐Iqbal,et al.  Alzheimer's disease, a multifactorial disorder seeking multitherapies , 2010, Alzheimer's & Dementia.

[27]  G. Nikkhah,et al.  Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. , 2009, Current protocols in stem cell biology.

[28]  N. Campillo,et al.  Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. , 2009, Mini reviews in medicinal chemistry.

[29]  Á. Martín-Requero,et al.  Enhanced proteasome-dependent degradation of the CDK inhibitor p27kip1 in immortalized lymphocytes from Alzheimer's dementia patients , 2008, Neurobiology of Aging.

[30]  Á. Martín-Requero,et al.  Impaired apoptosis in lymphoblasts from Alzheimer’s disease patients: Cross-talk of Ca2+/calmodulin and ERK1/2 signaling pathways , 2007, Cellular and Molecular Life Sciences.

[31]  A. Makriyannis,et al.  Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: Open-field examination in rats , 2006, Pharmacology Biochemistry and Behavior.

[32]  G. Uhl,et al.  Discovery of the Presence and Functional Expression of Cannabinoid CB2 Receptors in Brain , 2006, Annals of the New York Academy of Sciences.

[33]  O. Bachs,et al.  The Diverging Roles of Calmodulin and PKC in the Regulation of p21 Intracellular Localization , 2006, Cell cycle.

[34]  Rena Li,et al.  Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Alkon,et al.  Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice , 2005, Neurobiology of Aging.

[36]  P. Deyn,et al.  Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models , 2005, Neurochemistry International.

[37]  M. L. de Ceballos,et al.  Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.

[38]  K. Herrup,et al.  Divide and Die: Cell Cycle Events as Triggers of Nerve Cell Death , 2004, The Journal of Neuroscience.

[39]  R. Weiss.  p21Waf1/Cip1 as a therapeutic target in breast and other cancers. , 2003, Cancer cell.

[40]  B. Martin,et al.  Cannabinoid pharmacological properties common to other centrally acting drugs. , 2003, European journal of pharmacology.

[41]  O. Coqueret,et al.  New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? , 2003, Trends in cell biology.

[42]  C. Geula,et al.  Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.

[43]  C. Masters,et al.  Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease , 2002 .

[44]  M. Mesulam,et al.  Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine , 2002, Neuroscience.

[45]  M. L. de Ceballos,et al.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. , 2001, Cancer research.

[46]  S. Brimijoin,et al.  Abundant Tissue Butyrylcholinesterase and Its Possible Function in the Acetylcholinesterase Knockout Mouse , 2000, Journal of neurochemistry.

[47]  M. Weinstock,et al.  Effect of rivastigmine on scopolamine-induced memory impairment in rats. , 1999, European journal of pharmacology.

[48]  D. Ibarreta,et al.  Altered Ca2+ homeostasis in lymphoblasts from patients with late-onset Alzheimer disease. , 1997, Alzheimer disease and associated disorders.

[49]  C. Geula,et al.  Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia , 1994, Annals of neurology.

[50]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[51]  M. Herkenham,et al.  Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[52]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[53]  N. Campillo,et al.  Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's disease and Less Well-Known Diseases. , 2018, Current medicinal chemistry.

[54]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[55]  R. Hampson,et al.  Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons , 2003, Hippocampus.

[56]  C. Masters,et al.  Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. , 2002, Annals of neurology.